Table 1 Key clinical inputs

Clinical cure (1^st) of CTZ/TAZ

60.7

61.0

72.0

[14, 21]

Clinical cure (1^st) of MEPM

57.1

49.0

75.0

Mortality (1^st) of CTZ/TAZ

20.1

20.0

31.0

Mortality (1^st) of MEPM

25.5

12.0

28.0

Clinical cure (2^nd) of CTZ/TAZ

56.8

57.1

69.2

Clinical cure (2^nd) of MEPM

52.8

43.9

72.5

Mortality (2^nd) of CTZ/TAZ

24.1

24.0

37.2

Mortality (2^nd) of MEPM

30.6

14.4

33.6

Administration duration (Day)

 1^st-line treatment of CTZ/TAZ

8

7.64

8.36

[18]

 1^st-line treatment of MEPM

8.23

7.86

8.6

 2^nd-line treatment of CTZ/TAZ

7

4

10

[10]

 2^nd-line treatment of MEPM

7

4

10

ICU LOS (day)

 1^st-line treatment of CTZ/TAZ

28.0

16

28

[21]

 1^st-line treatment of MEPM

24.0

15

28

 2^nd-line treatment of CTZ/TAZ

21.0

20

23

 2^nd-line treatment of MEPM

21.0

20

23

Mechanical ventilation duration (Day)

 1^st-line treatment of CTZ/TAZ

12

5

28

[21]

 1^st-line treatment of MEPM

13

6

28

 2^nd-line treatment of CTZ/TAZ

12

5

28

 2^nd-line treatment of MEPM

12

5

28

Adverse Event rate (%)

 Septic shock of CTZ/TAZ

3.6

[14]

 Multiorgan failure of CTZ/TAZ

3.9

 Acute cardiac failure of CTZ/TAZ

2.5

 Septic shock of MEPM

4.7

 Multiorgan failure of MEPM

2.8

 Acute cardiac failure of MEPM

2.2

 Acute renal failure of AMK

6.0

0.0

27.6

[23]